Interpace Biosciences (OTCMKTS:IDXG) Issues Quarterly Earnings Results

Interpace Biosciences (OTCMKTS:IDXG) announced its quarterly earnings data on Monday. The business services provider reported $0.01 earnings per share for the quarter, Zacks reports. Interpace Biosciences had a return on equity of 219.07% and a net margin of 65.25%.

Interpace Biosciences Trading Up 5.6%

IDXG stock traded up $0.09 during mid-day trading on Monday, reaching $1.70. The company’s stock had a trading volume of 13,703 shares, compared to its average volume of 6,815. The company’s 50 day moving average is $1.61 and its two-hundred day moving average is $1.77. Interpace Biosciences has a fifty-two week low of $0.77 and a fifty-two week high of $2.40. The stock has a market cap of $7.53 million, a PE ratio of -34.00 and a beta of 0.61.

About Interpace Biosciences

Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.